Fairvalue-Calculator Fairvalue-Calculator
EN DE

Li Kang Biomedical Co (6242) Fair Value & Analysis

Consumer Cyclical · TW · Market cap 1.2B TWD

Price36.65 TWD
Fair Value41.87 TWD
Upside+14.2%
Quality95/100
Evidence: Medium Range 29.31 TWD – 54.43 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Li Kang Biomedical Co (6242) currently trades at 36.65 TWD, while our model-based Fair Value estimate is 41.87 TWD — implying the stock looks roughly 14.2% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

Booking Holdings (BKNG) -14% Airbnb, Inc (ABNB) -34% Royal Caribbean Cruises Ltd (RCL) -54% Viking Holdings (VIK) -41% Carnival Corporation (CCL) -29% Trip.com Group (9961) +112%

Frequently asked questions

Is Li Kang Biomedical Co (6242) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 41.87 TWD versus a price of 36.65 TWD — about +14% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6242?
Our 21-model fair value for Li Kang Biomedical Co is 41.87 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 36.65 TWD.
What is the quality score of 6242?
Li Kang Biomedical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.